<div id="readability-page-1"><div><p>General Proximity announced a strategic multi-target collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute in Boston to apply General Proximity's proprietary OmniTAC discovery platform to oncology programs of interest to Daiichi Sankyo. Induced proximity medicines enable the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets. The approach uses small molecules to bring two proteins into close physical proximity and subsequently induce a desired therapeutic effect.</p><p>The OmniTAC platform allows unbiased screening for effector proteins capable of modulating disease-relevant targets, offering a powerful and differentiated approach to drug discovery. Under the terms of the collaboration, General Proximity will leverage OmniTAC to discover and characterize novel effector-target pairs with the potential to generate first-in-class therapeutic candidates. In parallel with this collaboration, General Prox proximity will continue to expand the reach of its OmniTAC platform by leveraging the precise control of proximity to address undruggable targets across multiple disease areas.</p><p>In addition to oncology, the company is advancing programs in cardiometabolic disease, neurodegeneration, and longevity, underscoring its commitment to translating breakthrough science into transformative therapies for patients worldwide.</p></div></div>

第一三共株式會社(ADR)

<p>General Proximity 宣佈與第一三共株式會社（ADR）建立戰略合作關係，利用其 OmniTAC 發現平台進行腫瘤學項目。此次合作旨在開發誘導接近藥物，針對致病蛋白，創造以前無法藥物化的靶點的治療機會。該合作將專注於發現潛在的首創療法的新型效應器 - 靶點對，同時還將擴展 OmniTAC 在心代謝疾病、神經退行性疾病和長壽領域的應用</p>

General Proximity 宣佈與第一三共株式會社 (ADR) 達成戰略性多目標合作